Abstract: Just like other conducting polymers, polyanilines are useful for many important electric and electrooptical applications. A self-doped polyaniline that contains a stable/immobile, covalently bonded acid moiety on the backbone is highly desired, due to their greater resistances to solvent-washing, rain-flushing, and thermal evaporation. The present invention discloses a new type of thermally stable self-doped functionalized polyanilines that are thermally much more stable than the previously reported sulfonated-polyaniline, which was believed to be the most thermally stable self-doped polyaniline known in the art. The present invention also discloses a new and effective method for making this new type of thermally stable self-doped functionalized polyanilines.

Abstract: High heat polyethersulfone compositions are provided which possess unexpectedly high glass transition temperatures. The polyethersulfone compositions comprise structural units derived from phthalimide bisphenols such as 3,3-bis(4 -hydroxyphenyl)-N-phenylphthalimide, and structural units derived from at least one biphenyl-bissulfone such as 4,4?-bis((4-chlorophenyl)sulfonyl)-1,1?-biphenyl. The novel polyethersulfone compositions may further comprise structural units derived from one or more biphenols such as 4,4?-biphenol, bisphenols such as BPA, or other electrophilic sulfone monomers, such as bis(4-chlorophenyl)sulfone. In one embodiment, the polyethersulfone composition of the present invention comprises structural groups derived exclusively from 3,3-bis(4-hydroxyphenyl)-N-phenylphthalimide, and 4,4?-bis((4-chlorophenyl)sulfonyl)-1,1?-biphenyl and exhibits a single glass transition of greater than 300° C.

Abstract: The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.

Abstract: The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent.

Abstract: Novel semaphorin Z; a gene thereof; a partial peptide of the semaphorin Z; an antibody; a DNA or an RNA complementary to the semaphorin Z gene; a method for screening a semaphorin Z inhibitor by using the semaphorin Z; the semaphorin Z inhibitor obtained by the screening; and a CNS neuron regeneration promoter comprising the inhibitor.

Abstract: Disclosed herein are modified plant zinc finger proteins; compositions comprising modified plant zinc finger proteins and methods of making and using modified plant zinc finger proteins. The modified plant zinc finger proteins, in contrast to naturally-occurring plant zinc finger proteins, have a binding specificity that is determined by tandem arrays of modular zinc finger binding units.

Abstract: A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).

Abstract: The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin inhibitor to inhibit lectin complement pathway associated complement activation. The mannan binding lectin inhibitor may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin inhibitor. The mannan binding lectin inhibitor is an isolated mannan binding lectin binding peptide that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention provides polypeptide and polynucleotide splice variants of the mouse Mdm2 gene, including Mdm2-b, which is homologous to the human Hdm2-b variant, as well as host cells, vectors and transgenic mice comprising the variants, and methods for the use thereof.

Abstract: A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecules or construct and recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product of that nucleic acid and antibodies obtainable by immunization of an animal therewith, as well as use of the antibodies in screening methods for the identification of tumors.

Abstract: Recombinant laminin B1k and fragments thereof.

Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

Abstract: This disclosure provides gene sequence of a novel gene DaRub1 of Deschampsia antarctica expressed at low temperatures. The promoter sequence of this gene is identified and characterized. The promoter is inducible at low temperature, upon wounding and after auxin-treatment. Additionally this disclosure shows improved low temperature tolerance of transgenic Eucalyptus plants expressing DaRub1 gene.

Abstract: The invention relates to antisense oligonucleotides, in particular to antisense oligonucleotides to receptor genes, and the use of such oligonucleotides to regulate reproductive function and as chemopreventive or as a chemotherapeutic for various cancers, especially ovarian cancers. The invention also provides a method for preventing estrogen synthesis, a function of developing ovarian follicles, a therapeutic consideration for the prevention and treatment of some cancers of the breast, endometrium, ovary and cervix and of some endometriosis. The invention also relates to pharmaceutical compositions containing antisense oligonucleotides (ODNs, having 8 to 60 nucleotides) that act by binding to intracellular molecular targets. Optionally, for efficient delivery to a target DNA, RNA or protein, the ODNs may be covalently linked to a carrier moiety, which facilitates delivery of the ODN to the cytosol.

Abstract: Improved methods for synthesis of oligonucleotides and other phosphorus-linked oligomers are disclosed. The methods include the use of aromatic solvents, alkyl aromatic solvents, halogenated aromatic solvents, halogenated alkyl aromatic solvents, or aromatic ether solvents to achieve deprotection of protected hydroxyl groups.

Abstract: A 3-branched asparagine-linked oligosaccharide derivative of the formula (1) wherein the nitrogen of amino group of asparagine is modified with a lipophilic protective group, biotin group or FITC group; a 3-branched asparagine-linked oligosaccharide derivative which contains at least one fucose in N-acetylglucosamine on the nonreducing terminal side of the asparagine-linked oligosaccharide of the derivative; asparagine-linked oligosaccharides and oligosaccharides thereof wherein Q is a lipophilic protective group, biotin group or FITC group.

Abstract: A process for the preparation of 3-methylcepham-4-carboxylate of the formula (I). wherein R2 and R3 may be same or different and represent hydrogen, halogen, amino, alkyl, phenacetamido, substituted acetamido, phthalimido with a proviso that both R2 and R3 are not NH2, phenacetamido, phthalimido and the like; R1 represents a lower alkyl, p-methoxybenzyl, p-nitrobenzyl, o-nitrobenzyl, o-methoxybenzyl, o-chlorobenzyl or diphenylmethyl group, or a suitable ester residue which can be deprotected at a latter stage, L represents a leaving group; which comprises cyclizing the compound of formula (III) using a cyclizing agent in the presence of organic or inorganic nitrites and a solvent at a temperature in the range of ?40° C. to +60° C. to obtain compound of formula (I).

Abstract: Novel oxazole and thiazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.

Abstract: Tazarotene is prepared by deoxygenation of the corresponding S-oxide, in turn obtained according to two alternative synthetic pathways.

Abstract: This invention relates to a new process for the preparation of novel substituted haloarene compounds of the formula I or IV: respectively, wherein R1, R2, R3, R4, R5, X, and Y are as defined herein, that comprises a novel and efficient selective mono-lithiation of a dihaloarene of the formula II or V: respectively, by an organo-lithium compound in the presence of a carbonyl reactant of the formula III: wherein R1 and R2 are as defined herein. In the process of the instant invention, the newly formed lithiated haloarene is sequentially quenched in situ by the carbonyl reactant to form said substituted haloarene. The process is suitable for batch or continuous flow systems.

Abstract: Provided are methods for preparing a compound of Formula I: where the method comprises the steps of: contacting a compound of Formula II: with 1,3,5-benzene-tricarbonyl chloride in the presence of a polar aprotic solvent to form an amide adduct; and subsequently condensing the amide with a proximate anilino group present in the adduct in the presence of a condensing agent to form a compound of Formula I wherein R1, R2, Ar, m, p, and t are as defined in the specification.

Abstract: Bisimine compounds of the formula (I) where the symbols have the following meanings: A is a nonmetal selected from among N, S, O and P, R1 is a radical of the formula NR5R6, R2 is a radical of the formula NR5R6 or NR7R8, alkyl, aryl or cycloalkyl, R5 and R6 together with the N atom form a 5-, 6- or 7-membered ring in which one or more of the —CH— or —CH2— groups may be replaced by suitable heteroatom groups and which may be saturated or unsaturated and unsubstituted or substituted or be fused with further carbacyclic or heterocarbacyclic 5- or 6-membered rings which may in turn be saturated or unsaturated and substituted or unsubstituted, and R7 and R8 are, independently of one another, alkyl, aryl or cycloalkyl radicals, and R3, R4 are, independently of one another, H or alkyl, aryl or cycloalkyl radicals, and n is 1 or 2, are used to prepare bisimidinato complexes which can be used in the polymerization of unsaturated compounds.

Abstract: A process of preparing an olefin oxide, preferably propylene oxide, and an alcohol, such as ?-ethylphenyl alcohol, the process involving contacting an olefin, such as propylene, and an organic hydroperoxide, such as ethylbenzene hydroperoxide, in the presence of an epoxidation catalyst, preferably, a homogeneous molybdenum catalyst, in a single reactor system or in a multi-reactor system containing a plurality of sequentially interconnected reactors. Each reactor in the single or multi-reactor system is preferably divided into a plurality of reaction zones designed to facilitate plug flow behavior. The olefin is fed to a first reaction zone in the single reactor system or to a first reactor in the multi-reactor system. The organic hydroperoxide feed is split into a plurality of split organic hydroperoxide feedstreams, and the split feedstreams are distributed throughout the reaction zones, or the reactors, or both.

Abstract: A water-stable and water-soluble ceramic precursor is provided, containing at least one Group III element. Also, a metal acid salt complex is provided comprising (1) bismuth, lanthanum, and titanium, and (2) a polyether acid. In addition, methods are provided for preparing the Group III metal acid salt complex and the Bi, La, Ti acid salt complex comprising a bismuth polyether acid salt complex, a lanthanum polyether acid salt complex, and a titanium polyether acid salt complex. Finally, devices that include lanthanum-doped bismuth titanate as the active component are provided, as well as a water-stable and water-soluble gallium polyether acid complex.

Abstract: A novel process for the preparation of high-purity zirconium, hafnium, tantalum and niobium alkoxides (alcoholates), novel tantalum and niobium compounds and a process for their preparation are provided. The process comprises the steps of mixing crude metal alkoxides M(OR)x having a halogen impurity of at least 0.05 wt. %, with an alcohol ROH, in which R is a C1-C12-alkyl radical, and subsequently or simultaneously metering in an excess of ammonia, based on the amount of mononuclear or polynuclear halogen-containing metal alkoxides.

Abstract: Provided are preservation formulations and methods, e.g., formulations for the preservation of wood. In particular, provided are methods for the production of copper monoethanolamine aqueous solutions from metallic copper and monoethanolamine.

Abstract: The invention describes a process for preparing alkoxylated, phosphorus-containing compounds, using heterogeneous catalysts based on metal oxides of aluminum, so that the product can be worked up anhydrously.

Abstract: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: A process for reducing the content of ethyl 3-dimethylamino-2-phenylpropionate in a solution, contaminated therewith, of ethyl 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate in a water-immiscible solvent, which comprises adding from 0.5 to 2.0 equivalents of a carboxylic acid per mole of ethyl 2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate to this solution, and stirring this mixture at a temperature of from 50° C. to 100° C., is described.

Abstract: A probucol or a probucol derivative can be efficiently converted to a monoester or monoether of probucol by reacting the free hydroxyl-containing probucol or a derivative thereof (by which is meant a probucol compound with at least one substituent that is different from that on the parent probucol molecule but which maintains the two free hydroxyl groups) with a Grignard reagent or a lithium reagent that produces a magnesium bromide or lithium salt of probucol or the probucol derivative. The probucol compound anion anion is then reacted with an ester or ether forming compound.

Abstract: Disulfonate salts of 2,4-pentanedione and methods for making such salts are described. The disulfonate salts are useful as cement dispersants. Cement compositions including such salts, methods for making cement compositions including such salts, and methods for performing cementing operations using such cement compositions are also described.

Abstract: A method and apparatus for the conversion of aromatic alkyls to aromatic carboxylic acids in a reactor are provided, wherein the location of the feeding of the reaction mixture into the reactor significantly increases the conversion efficiency of the precursor materials.

Abstract: Polyhydroxy phenols, which are non-peptidic mimetics of galloyl peptides, and a process for the preparation of gallic acid derivatives using a gallic-acid providing moiety are provided as well as polyhydroxy phenol-containing pharmaceutical and nutraceutical compositions. The use of polyhydroxy phenols as a medicament and especially for the manufacture of a medicament for the prevention, treatment or diagnosis of a disease or a condition, wherein P-selectin is involved, is provided. The same compounds can also be used as targeting tools to P-selectin expressing cells or tissues in a composition, further comprising an active compound in a vehicle.

Abstract: Substituted C-cyclohexylmethylamine derivatives, methods for the production thereof, pharmaceuticals containing said compounds, the use of substituted C-cyclohexylmethylamine derivatives for producing pharmaceuticals, and method of pain treatment using the pharmaceuticals.

Abstract: A process for producing an arylamine is provided which is characterized by reacting an aromatic halogen compound with an aromatic amine in the presence of an organic salt selected from specific pyridinium salts, imidazolium salts and quaternary onium salts, a copper catalyst, and a base. Thus, the reaction of even an aromatic halogen compound substituted by an electron-donating group proceeds efficiently, and an inexpensive chlorinated aromatic compound or brominated aromatic compound is usable, and an arylamine, in particular a triarylamine or diarylamine, having a high purity can be produced at low cost.

Abstract: The invention relates to a catalytic method for the production of aliphatic and aromatic carbonyl compounds with at least one aldehyde or ketone function, whereby said compounds can also comprise at least one aldehyde and ketone function. A starting material comprising at least one aliphatic- and/or aromatic-bonded functional group of formula (I), where R1=H, alkyl or aryl, X=H, or a group which may be substituted by the sulphinyl group of a sulphoxide during the catalytic reaction, n=a whole number from 1 to 8, is oxidised in the presence of a sulphoxide and/or a sulphide and the presence of iron salts or redox pairs of iron/copper or silver/copper salts, by means of an oxidising agent with a redox potential of Eo>+2 V vs. NHE, whereby the sulphoxide or sulphide has a catalytic function.

Abstract: Method of stabilizing high-concentration formaldehyde solutions having a CH2O content of >70% by weight against precipitation of solids, which comprises heating the high-concentration formaldehyde solution at a heating rate of at least 5° C./min to a temperature of from 80° C. to 200° C. immediately after it has been prepared and storing it at a temperature in this range.

Abstract: Alkali metal salt of formula (I): MOYXR1 (I), and its solution can be prepared in high yields, particularly high space-time yields, and with high purities by reacting an alcohol of the formula (Ia): HOYXR1 (Ia), in a solvent mixture with an alkali metal salt of formula (II): MOR2 (II), or by reacting the alcohol (Ia) in a solvent mixture with an alkali metal hydroxide. Part of the liberated alcohol of formula (IIa): HOR2 (IIa) or a part of the liberated water is distilled from the solvent mixture, initially, without addition of an entrainer. Subsequently, a remainder of the liberated alcohol of formula (IIa) or the liberated water is distilled from the solvent mixture with the aid of at least one organic solvent as entrainer. In formula (I) and in formula (II), M is Li, Na, K, Rb or Cs.

Abstract: A process for the production of gasoline stocks wherein lower molecular weight olefins are first oligomerized and the oligomers then hydrogenated. In the first instance the oligomerization is carried out in a single pass fixed bed boiling point reactor. The oligomers are then hydrogenated in a distillation column reactor.

Abstract: A process for the production of an isomerate with a RON that is at least equal to 80 and that contains less than 1% by weight of aromatic compounds, starting with a fraction consisting mostly of hydrocarbons with 7 carbon atoms, and containing paraffins, naphthenes, and aromatic compounds in any proportion is described. Said process uses at least one isomerization unit, at least one unit for opening naphthene rings, and at least one separation unit; these units are combined in such a way as to recycle, to exhaustion, methyl cyclohexane, toluene, and normal paraffins and monobranched paraffins.

Abstract: A catalyst composition suitable for the trimerization of olefinic monomers, wherein the catalyst composition comprises: a) a source of chromium, molybdenum or tungsten; b) a ligand of general formula (I); (R1)(R2)P—X—P(R3)(R4)??(I) wherein: X is a bivalent organic bridging group; R1 and R3 are independently selected from, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl and substituted heterohydrocarbyl groups, with the proviso that when R1 and R3 are cycloaromatic groups they do not contain a polar substituent at any of the ortho-positions; R2 and R4 are independently selected from optionally substituted cycloaromatic groups, each R2 and R4 bearing a polar substituent on at least one of the ortho-positions; and c) a cocatalyst.

Abstract: A reactor apparatus and related method for controlling at least one process variable in a circulating fluid bed oxygenates to olefins reactor system comprising a riser are provided. The process variable is selected from at least one of (i) space velocity, (ii) average reaction temperature, (iii) conversion of reactant, and (iv) average coke level on catalyst. Typically, a corresponding set point for at least one process variable is selected from (1) reactant feed rate, (2) feed enthalpy, (3) reactor temperature-related function, e.g., mid-temperature or rate of temperature rise along a portion of the reactor, and (4) catalyst hold-up in the riser of the reactor. A corresponding manipulated variable is selected from (a) feed flow control valve(s), (b) feed preheat rate, (c) activity of the catalyst in the reactor, and (d) amount of catalyst in the reaction zone.

Abstract: The present invention is a process for quenching a reactor effluent stream. The reactor effluent stream comprises water, olefin product, and methanol and is further entrained with catalyst fines. The process removes water, catalyst fines, and methanol. Particularly, methanol removal from the reactor effluent stream is improved.

Abstract: Devices, such as solid supports having metal binding proteins, such as metallothionein proteins, bound thereto are disclosed for removing metals from substrates in need of having such metals removed therefrom. Specifically membranes having metallothionein proteins from the brine shrimp Artemia are disclosed for removing metals from liquid substrates. Associated methods for removing metals from substrates using metallothionein proteins are also disclosed.

Abstract: The present invention features a non-human animal model of malaria, e.g., Plasmodium, particularly Plasmodium falciparum. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.

Abstract: A non-human transgenic animal that is transgenic for an antibody or fragments thereof and having a phenotype reminiscent of human pathology. The human pathology includes neurodegenerative syndromes, muscular atrophy/dystrophy and immune disorders. The animals may be used in a method for early diagnosis of neurodegenerative diseases. The method includes monitoring the occurrence of the tau hyperphosphorylation and/or amyloid deposition in the back or lower limb skeletal muscle sample of a subject. Cells are derivable from the non-human transgenic animal and secreting the transgenic antibody. The cells are used for the selection of molecules pharmacologically effective in neurodegenerative and/or muscular pathologies and/or immune disorders.

Abstract: Methods for protecting a plant from a plant pathogenic fungus are provided. A method for enhancing fungal pathogen resistance in a plant using the nucleotide sequences disclosed herein is further provided. The method comprises introducing into a plant an expression cassette comprising a promoter operably linked to a nucleotide sequence that encodes an antifungal polypeptide of the invention. Transformed plants, plant cells, seeds, and microorganisms comprising a nucleotide sequence that encodes an antifungal polypeptide of the embodiments, or variant or fragment thereof, are also disclosed.

Abstract: This present invention provides a method for increasing fatty acid synthase activity in a plant by expressing a transgenic multifunctional fatty acid synthase (mfFAS) within the plant, wherein the plant is not of the Brassica species. In one embodiment, the present invention provides isolated nucleic acid molecules encoding mfFAS proteins from various sources for this purpose, and vectors containing same.

Abstract: The present invention relates to a promoter directing high levels of expression of a gene in plant storage roots, derived from the sweet potato MADS-box gene, a vector directing high levels of expression of a gene in plant storage roots comprising the same and a transient assay method expressing a foreign gene transiently in plant storage roots using the same vector. The promoter according to the present invention can induce high levels of expression particularly in plant storage roots. Therefore the present invention is very useful for the development of transgenic plants to produce valuable materials in large quantities in plant storage roots.